Zhejiang Nhu Co Ltd (002001) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Zhejiang Nhu Co Ltd stock ¥47.84, price ¥26.85, upside +78.2%, quality 77 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range ¥13.37 – ¥38.27 · fair‑value band ¥33.49 – ¥62.20 · the ¥26.85 price screens below the ¥47.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Zhejiang Nhu Co in your weekly email
Every Wednesday you see whether Zhejiang Nhu Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhejiang NHU Company Ltd., together with its subsidiaries, produces and sells nutritional products, fragrances and flavors, polymer materials, and active pharmaceutical ingredients in China and internationally. It operates through Pharmaceutical and Chemical; and Other segments.
Show moreShow less
The company offers animal nutrition products comprising vitamins, amino acids, and carotenoids for poultry, swine, ruminants, and farmed fish; human nutrition products consisting of vitamins A, D3, E, H, C, B5, B6, and B12, as well as coenzyme Q10, beta carotene, taurine, and l-serine for use in nutritional supplements, food and beverages, and personal care applications; and flavor and fragrance products, including fruity, floral, and green/herbal products for use in soap, toothpaste, shampoo, skin care products, and food and beverage products.
It also provides pigments; methionine, biotin, cysteine, and tryptophan; linalool, citral, leaf alcohol, methyl dihydrojasmonate, raspberry ketone, privet aldehyde, and menthol; PPS and PPA resins, PPS fibers, LTF composite materials, and PPS cast films and heat pipes; chemical products, such as prenol, l-ascorbic acid, acrylic acid, acrolein, sodium thiomethoxide in H2O, acrolein cyanohydrin acetate, diethyl oxalate/oxalic acid diethyl ester, potassium sulfate, ammonium sulfate, isophorone, cyclopentanone, and isovaleraldehyde for use in construction chemicals, crop protection, fertilizers, industrial solvents, and intermediates.
In addition, the company offers active pharmaceutical ingredients, vitamins, and pharmaceutical intermediates, as well as professional services for preparation companies. The company exports its products.
The company was incorporated in 1999 and is headquartered in Xinchang, the People's Republic of China. Zhejiang NHU Company Ltd. operates as a subsidiary of NHU Holding Group Co.,Ltd.
Stock analysis
Zhejiang Nhu Co Ltd (002001) currently trades at ¥26.85, while our model-based Fair Value estimate is ¥47.84, implying the stock looks roughly 44% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥62.47 per share, and 20 of the 26 models we run sit above the ¥26.85 price.
Bear case: the Dividend Discount group reads lowest at ¥16.34, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥33.49 (bear) to ¥62.20 (bull), the price of ¥26.85 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 77/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Zhejiang Nhu Co Ltd reported revenue of 22.3B CNY in FY2025 versus 14.9B CNY in FY2021, a compound +10.5%/yr. Reported net income was 6.8B CNY in FY2025, compounding +11.6%/yr from FY2021.
Key figures
Market cap 82.5B CNY (≈ $12.4B) Large · P/E ratio 10.9 · P/S ratio 3.32 · EPS (TTM) ¥2.46 · Dividend yield 3.7% · Net margin 29.4% · Return on equity 21.3% · Return on assets (EBIT) 13.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 84 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 78%, 002001 screens cheaper than that median.
Fair Value models
Bear¥33.49Fair Value ¥47.84Bull¥62.20
Price ¥26.85 · Upside +78.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥1.24 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.6%
Start year 2020 (pandemic). Over 10 years: +19.3% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+17.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.5%
Dividend (yield on the price)3.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.13.8% vs 22.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.40% → 36%
2025 sits 87% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −4.6% a year for the price and +5.4% for the forecasts.
AI conclusion: Strong reported margins and operational resilience support the specialty generics and nutrition business, yet limited visible moat signals leave it exposed to typical generic price pressures.
Main risk: Additional capacity from domestic peers and global players such as Adisseo or Evonik could increase supply and exert downward pressure on methionine prices and margins.
Bull case: By leveraging its proprietary clean synthesis technologies and cost advantages the company could capture share from higher-cost overseas rivals amid supply disruptions and maintain resilient margins in methionine and vitamins.
Bear case: If peer capacity ramps up faster than demand or environmental compliance costs surge the company could face sustained price erosion and margin compression in its core nutrition segments.
Zhejiang NHU continues executing its share repurchase program while advancing new materials projects and expanding its nutrition segment, particularly methionine. Strong half-year revenue and profit growth highlight operational resilience in a specialty generics and health care chemicals business. Yet the shares remain well below their recent peak. Will the ongoing buybacks and internationalization efforts lift valuations before sector headwinds or project execution risks weigh in?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 554 stocks
Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score77 · Top 25%
Fair Value upside+78.2% · Top 25%
Profitability
Return on equity (12 months)21.3% · Top 25%
Return on assets14.8% · Top 25%
Net margin (12 months)29.4% · Top 25%
Operating margin (12 months)36.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)10.1% · Above median
Dividend yield (12 months)3.7% · Top 25%
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhejiang Nhu Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002001
Frequently asked questions
Is Zhejiang Nhu Co Ltd (002001) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥47.84 versus a price of ¥26.85, about +78% upside (undervalued).
What is the fair value of 002001?
Our model-based fair value for Zhejiang Nhu Co Ltd is ¥47.84 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥26.85.
What is the quality score of 002001?
Zhejiang Nhu Co Ltd has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Nhu Co Ltd (002001)?
Our model-based price target is the fair value of ¥47.84 (as of Nov 5, 2026) from 26 valuation models. Cautious scenario ¥33.49, optimistic scenario ¥62.20. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang Nhu Co Ltd stock forecast for 2026?
Our models put fair value at ¥47.84, about +78% upside versus a price of ¥26.85 (undervalued). Cautious scenario ¥33.49, optimistic scenario ¥62.20. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Nhu Co Ltd (002001)?
Zhejiang Nhu Co Ltd reported trailing-twelve-month revenue of about 24.8B CNY (latest available figure, as of Nov 5, 2026).
Does Zhejiang Nhu Co Ltd pay a dividend?
Zhejiang Nhu Co Ltd currently shows a dividend yield of 3.72% relative to its recent price (as of Nov 5, 2026).
What growth is priced into Zhejiang Nhu Co Ltd (002001)?
For today's price to be fair in a discounted-cash-flow model, Zhejiang Nhu Co Ltd would have to grow free cash flow by -3.0 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +16.6 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 002001 use?
Our models discount Zhejiang Nhu Co Ltd at 8.7 %: a base by market capitalisation (large), damped by beta 0.26, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Zhejiang Nhu Co Ltd that is -3.0 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Zhejiang Nhu Co Ltd (002001) delivered so far?
Over the past 5 years revenue at Zhejiang Nhu Co Ltd grew +16.6 % a year. The price currently implies -3.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Zhejiang Nhu Co Ltd (002001) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Zhejiang Nhu Co Ltd (-3.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Zhejiang Nhu Co Ltd (002001)?
The free-cash-flow yield on the price is 8.36 %: that much free cash flow Zhejiang Nhu Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Zhejiang Nhu Co Ltd (002001)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Nhu Co Ltd it is ¥47.84 per share (as of Nov 5, 2026), against a price of ¥26.85. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Zhejiang Nhu Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 002001 trades below its calculated fair value: price ¥26.85, fair value ¥47.84, a gap of about +78% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002001?
No. The price is what the market pays today (¥26.85); the fair value is what the company's own numbers justify (¥47.84). For Zhejiang Nhu Co Ltd the two are ¥20.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Nhu Co Ltd worth?
The market values Zhejiang Nhu Co Ltd at about 82.5B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥26.85; our models calculate a fair value of ¥47.84 per share.
What do the bullish and bearish scenarios say about 002001?
Our models span a range for Zhejiang Nhu Co Ltd: cautious scenario ¥33.49, base ¥47.84, optimistic ¥62.20 per share (as of Nov 5, 2026, price ¥26.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002001?
Zhejiang Nhu Co Ltd trades at a price-to-earnings ratio of 10.9 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥47.84 is built from several models across several years. Other multiples: PEG 0.1, P/B 2.5, P/S 3.3, EV/EBITDA 7.4.
What is the PEG ratio of 002001?
The PEG ratio of Zhejiang Nhu Co Ltd is 0.07 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Zhejiang Nhu Co Ltd (002001)?
Balance-sheet figures for Zhejiang Nhu Co Ltd (as of Nov 5, 2026): return on equity 21.3%, debt of 0.13 per unit of equity. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is 002001 from its 52-week high?
Zhejiang Nhu Co Ltd trades at ¥26.85, about 30% below its 52-week high of ¥38.27 and 16% above the low of ¥23.23 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of ¥47.84 is for.
Which stocks are comparable to Zhejiang Nhu Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Nhu Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price ¥26.85, calculated fair value ¥47.84 (+78%), Quality Score 77/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002001 calculated?
We run Zhejiang Nhu Co Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥47.84, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6% above its aggregate fair value. Zhejiang Nhu Co Ltd currently trades 44% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Nhu Co Ltd (002001)?
The closing price on Nov 5, 2026 was ¥26.85. Our model-based fair value is ¥47.84, about +78% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Nhu Co Ltd right now?
The rarer combination: high quality (77/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (¥33.49). The market is more pessimistic than our downside scenario. A fairly wide model range (¥33.49 to ¥62.20) leaves room in how you read the outcome.
Where does the earnings growth of Zhejiang Nhu Co Ltd (002001) come from?
Earnings per share at Zhejiang Nhu Co Ltd grew +19.7 % a year from 2013 to 2024. Broken into its drivers: revenue per share +15.7 %, EBIT margin +3.3 %, tax rate +0.5 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Zhejiang Nhu Co Ltd
How large is the market capitalisation of Zhejiang Nhu Co Ltd (002001)?
The market capitalisation of Zhejiang Nhu Co Ltd is 82.5B CNY (≈ $12.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Nhu Co Ltd (002001)?
The price-to-sales ratio of Zhejiang Nhu Co Ltd is 3.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang Nhu Co Ltd (002001)?
Earnings per share at Zhejiang Nhu Co Ltd are ¥2.46 (price ÷ EPS = P/E 10.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang Nhu Co Ltd (002001)?
The dividend yield of Zhejiang Nhu Co Ltd is 3.7% (payout 40.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang Nhu Co Ltd (002001)?
The net margin of Zhejiang Nhu Co Ltd is 29.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Nhu Co Ltd (002001)?
The return on equity (ROE) of Zhejiang Nhu Co Ltd is 21.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Nhu Co Ltd (002001)?
On an EBIT basis the return on assets of Zhejiang Nhu Co Ltd is 13.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Nhu Co Ltd (002001)?
The operating margin of Zhejiang Nhu Co Ltd is 36.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang Nhu Co Ltd (002001)?
Revenue at Zhejiang Nhu Co Ltd is growing +10.1% versus a year earlier (3y avg +11.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhejiang Nhu Co Ltd (002001)?
Earnings per share at Zhejiang Nhu Co Ltd are growing +7.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Zhejiang Nhu Co Ltd (002001) hold?
Zhejiang Nhu Co Ltd holds more cash than debt, 1.4B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Zhejiang Nhu Co Ltd in the live analysis
One click puts Zhejiang Nhu Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026